Showing 5111-5120 of 8624 results for "".
- Pulse Biosciences, Inc's CellFX System Performs Well in Sebaceous Hyperplasia Studyhttps://practicaldermatology.com/news/pulse-biosciences-incs-cellfx-system-performs-well-in-sebaceous-hyperplasia-study/2459987/Pulse Biosciences, Inc’s CellFX Nano-Pulse Stimulation system cleared more than 90 percent of sebaceous hyperplasia (SH) lesions in a study presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Candela Unveils New Corporate Identity at the 2019 AAD Annual Meetinghttps://practicaldermatology.com/news/candela-unveils-new-corporate-identity-at-the-2019-aad-annual-meeting/2459874/Syneron-Candela has rebranded the company to Candela and unveiled its new corporate branding at the American Academy of Dermatology (AAD) Annual Meeting. The new corporate identity reflects the unification of the Syneron and Candela brands and is designed to support continued global market growth
- Floodwaters and Climate Change Increase Risks for Dermatologic Diseasehttps://practicaldermatology.com/news/floodwaters-and-climate-change-increase-risks-for-dermatologic-disease/2459879/As more frequent and intense flooding disasters have occurred in conjunction with progressively rising temperatures, both disaster victims and relief workers have experienced significant dermatologic problems, according to
- FDA Clears Sculptura Radiation Oncology System from Sensus Healthcarehttps://practicaldermatology.com/news/fda-clears-sculptura-radiation-oncology-system-from-sensus-healthcare/2459884/The FDA has granted market clearance for the Sculptura radiation oncology system from Sensus Healthcare, Inc. With a single treatment during surgery, Sculptura can provide cancer patients and physicians a single radiation treatment at the
- Todd Wood Named DermTech's New Chief Commercial Officerhttps://practicaldermatology.com/news/todd-wood-named-dermtechs-new-chief-commercial-officer/2459883/Todd Wood is DermTech’s new Chief Commercial Officer. Mr. Wood will oversee the Sales and Marketing functions. With 25 years of pharmaceutical and medical device commercialization experience, Mr. Wood has launched multiple market leading product
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the exce
- Crown Laboratories Redesigns Blue Lizard Australian Sunscreen Line to Comply with Reef-Safe Legislationhttps://practicaldermatology.com/news/crown-laboratories-launches-redesigned-blue-lizard-australian-sunscreen-line/2459893/Crown Laboratories, Inc., has relaunched its redesigned, dermatologist-recommended Blue Lizard Australian Sunscreen. The company says the redesign includes new products, improved formulations, and a new aesthetic design concept across the entire portfolio based on a year of research to build on t
- SkinBioTherapeutics Raises Capital to Broaden Applications for Skin Biome Technologyhttps://practicaldermatology.com/news/skinbiotherapeutics-raises-capital-to-broaden-applications-for-skin-biome-technology/2459894/SkinBioTherapeutics raised close to $2M to widen potential applications for their skin biome technology, the company reports. Derived from probiotic bacteria, SkinBioTherapeutics technology is being developed for use in cosmetics, infectio
- FDA Proposes Policy for New Competitive Generic Therapies Pathwayhttps://practicaldermatology.com/news/fda-proposes-policy-for-new-competitive-generic-therapies-pathway/2459896/The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs) creates a designation that can be granted to a company submitting an application for their